Wednesday, March 28, 2012

Patient Centered Peostate Cancer Diagnosi &Treatment

WASHINGTON, D.C. (January 23, 2012) - The Patient-Centered Outcomes Research
Institute (PCORI) today released for public comment a first draft of its
National Priorities for Research and Research Agenda, which will be used to
guide funding announcements for comparative clinical effectiveness research
that will give patients and those who care for them the ability to make
better-informed health decisions.



The 53-day public comment period, which will end in mid-March, will be used
to solicit feedback and revise the priorities and agenda before a final
version of each is adopted by PCORI's Board of Governors.



"We want to hear from patients, caregivers, providers and the wider health
care community on whether our draft priorities and initial research agenda
capture the broad areas where more evidence-based information is needed to
make better decisions," said PCORI Board Chair Eugene Washington, M.D.,
M.Sc. "This is a major milestone in our work as we continue to collaborate
with all stakeholders and to build on the work of others for what we expect
will be the most patient-centered research agenda yet."



The draft National Priorities for Research identifies five areas where
comparative effectiveness research is needed to support decision-making:



    Assessment of Options for Prevention, Diagnosis, and Treatment

    Improving Health Care Systems;

    Communication and Dissemination Research;

    Addressing Disparities; and

    Accelerating Patient-Centered Outcomes Research and Methodological
Research.



_______________________________________________
ProstateCancerAction mailing list
ProstateCancerAction@malecare.com
http://mail.malecare.com/mailman/listinfo/prostatecanceraction_malecare.com

Sunday, February 26, 2012

New Provenge Clinical Trial


Clinical trial - NO placebo:Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Currently recruiting in Denver, Seattle, and Virginia Beach.  Contact info in link above.
Basic Eligibility Criteria:
  • Metastasis on Bone Scan or CT within 28 days before starting trial
  • PSA 2.0 or greater
  • Testosterone less than or equal to 50
  • Evidence of cancer progression
  • NO metastases to lung, liver, or brain
  • NO Xgeva (denosumab) within the last 3 months
  • NO treatment within the last 28 days with ANY of the following:
    • Proscar
    • Avodart
    • saw palmetto
    • DES
    • Megace
    • Casodex or Eulexin or Nilutamide
    • ketoconazole
 
This trial would give Zytiga (abiraterone) access for free to men who have NOT had chemo. Also access to PROVENGE no matter what your insurance policy is.  Print and discuss with your physician(s).
Hope this helps someone,
 
Jan Manarite
PCRI Senior Educational Facilitator
(310) 743-2110  or(239) 395-0995  DirectThe PROSTATE CANCER RESEARCH INSTITUTE is a registered non-profit organization. Visit us at www.PCRI.org
I am a prostate cancer researcher and advocate, not a medical professional. Information I share with you is to help expand your knowledge for discussion with your own physicians
and should not be considered actual medical advice.


Hi to All,

This trial looks promising.
Dick Gillespie 703/497-0628 
=

Wednesday, February 22, 2012

New Global Research Studies,elm*pc Studies

15587.bmp
Us TOO Homepage | Donate | View Message in Your BrowserUnsubscribe/Edit Preferences | Forward This Email


February 22, 2012
Dear
Dick,

As a reminder, two global research studies, called the elm•pc studies, are seeking men with metastatic castration-resistant prostate cancer to participate in the effort to evaluate a new investigational oral medication, TAK-700, given with prednisone.

The studies will help determine if TAK-700, given with prednisone, can lengthen the lives of men with metastatic castration-resistant prostate cancer compared to prednisone alone.
elm_pc_logo.jpg
Men enrolled in either study will be assigned to one of two groups: those who will receive the investigational oral medication, TAK-700, with prednisone, and those who will be treated with prednisone alone. Prednisone is asteroid commonly used to treat advanced prostate cancer.

TAK-700, an investigational oral lyase inhibitor, is being studied for individuals with metastatic prostate cancer.

The elm•pc studies are being conducted by Millennium: The Takeda Oncology Company. To learn more about the elm•pc studies call 1-855-493-5672 or visit  www.elmpctrials.com.

Please feel free to forward this message along to other men you know who are dealing with painful prostate cancer, or to physicians who might be interested in sharing the information with their other patients. Thank you in advance for your consideration and participation.

Tuesday, February 14, 2012




Thought you might like to see these!!! Comments made in the year 1957:

"I'll tell you one thing, if things keep going the way they are, it's going to be impossible to buy a week's groceries for $20."

"Have you seen the new cars coming out next year? It won't be long before $5000 will only buy a used one."

Tuesday, December 20, 2011

Johns Hopkins Update on Cancer Treatment

Johns Hopkins Update - Very Good Article

AFTER YEARS OF TELLING PEOPLE CHEMOTHERAPY
IS THE ONLY WAY TO TRY ('TRY', BEING THE KEY WORD) TO ELIMINATE CANCER,JOHNS HOPKINS IS FINALLY STARTING TO TELL YOU THERE IS AN ALTERNATIVE WAY .

Cancer Update from Johns Hopkins :

1. Every person has cancer cells in the body. These cancer
cells do not show up in the standard tests until they have
multiplied to a few billion. When doctors tell cancer patients
that there are no more cancer cells in their bodies after
treatment, it just means the tests are unable to detect the
cancer cells because they have not reached the detectable
size.

2. Cancer cells occur between 6 to more than 10 times in a
person's lifetime .

3. When the person's immune system is strong the cancer
cells will be destroyed and prevented from multiplying and
forming tumors.

4. When a person has cancer it indicates the person has
nutritional deficiencies. These could be due to genetic,
to environmental, food and lifestyle factors.

5. To overcome the multiple nutritional deficiencies, changing
diet and including supplements will strengthen the immune
system.

6. Chemotherapy involves poisoning the rapidly-growing
cancer cells and also destroys rapidly-growing healthy cells
in the bone marrow, gastrointestinal tract etc, and can
cause organ damage, like liver, kidneys, heart, lungs etc.

7. Radiation while destroying cancer cells also burns, scars
and damages healthy cells, tissues and organs.

8. Initial treatment with chemotherapy and radiation will often
reduce tumor size. However prolonged use of
chemotherapy and radiation do not result in more tumor
destruction.

9. When the body has too much toxic burden from
chemotherapy and radiation the immune system is either
compromised or destroyed, hence the person can succumb
to various kinds of infections and complications.

10. Chemotherapy and radiation can cause cancer cells to
mutate and become resistant and difficult to destroy.
Surgery can also cause cancer cells to spread to other
sites.

11. An effective way to battle cancer is to starve the cancer
cells by not feeding it with the foods it needs to multiply.

*CANCER CELLS FEED ON:

a. Sugar is a cancer-feeder. By cutting off sugar it cuts off
one important food supply to the cancer cells. Sugar
substitutes like NutraSweet, Equal, Spoonful, etc are made
with Aspartame and it is harmful. A better natural substitute
would be Manuka honey or molasses, but only in very small
amounts. Table salt has a chemical added to make it white in
color Better alternative is Bragg's aminos or sea salt.

b. Milk causes the body to produce mucus, especially in the
gastro-intestinal tract. Cancer feeds on mucus. By cutting
off milk and substituting with unsweetened soy milk cancer
cells are being starved.

c. Cancer cells thrive in an acid environment. A meat-based
diet is acidic and it is best to eat fish, and a little chicken
rather than beef or pork. Meat also contains livestock
antibiotics, growth hormones and parasites, which are all
harmful, especially to people with cancer.

d. A diet made of 80% fresh vegetables and juice, whole
grains, seeds, nuts and a little fruits help put the body into
an alkaline environment. About 20% can be from cooked
food including beans. Fresh vegetable juices provide live
enzymes that are easily absorbed and reach down to
cellular levels within 15 minutes to nourish and enhance
growth of healthy cells. To obtain live enzymes for building
healthy cells try and drink fresh vegetable juice (most
vegetables including bean sprouts) and eat some raw
vegetables 2 or 3 times a day. Enzymes are destroyed at
temperatures of 104 degrees F (40 degrees C).

e. Avoid coffee, tea, and chocolate, which have high
caffeine. Green tea is a better alternative and has cancer
fighting properties. Water-best to drink purified water, or
filtered, to avoid known toxins and heavy metals in tap
water. Distilled water is acidic, avoid it.

12. Meat protein is difficult to digest and requires a lot of
digestive enzymes. Undigested meat remaining in the
intestines becomes putrefied and leads to more toxic
buildup.

13. Cancer cell walls have a tough protein covering. By
refraining from or eating less meat it frees more enzymes
to attack the protein walls of cancer cells and allows the
body's killer cells to destroy the cancer cells.

14.. Some supplements build up the immune system
(IP6, Flor-ssence, Essiac, anti-oxidants, vitamins, minerals,
EFAs etc.) to enable the bodies own killer cells to destroy
cancer cells. Other supplements like vitamin E are known
to cause apoptosis, or programmed cell death, the body's
normal method of disposing of damaged, unwanted, or
unneeded cells.

15. Cancer is a disease of the mind, body, and spirit.
A proactive and positive spirit will help the cancer warrior
be a survivor. Anger, un-forgiveness and bitterness put
the body into a stressful and acidic environment. Learn to
have a loving and forgiving spirit. Learn to relax and enjoy
life.

16. Cancer cells cannot thrive in an oxygenated
environment. Exercising daily, and deep breathing help to
get more oxygen down to the cellular level. Oxygen
therapy is another means employed to destroy cancer
cells.

1. No plastic containers in micro.

2. No water bottles in freezer.

3. No plastic wrap in microwave.

Johns Hopkins has recently sent this out in its newsletters. This information is being circulated at Walter Reed Army Medical Center as well. Dioxin chemicals cause cancer, especially breast cancer. Dioxins are highly poisonous to the cells of our bodies. Don't freeze your plastic bottles with water in them as this releases dioxins from the plastic. Recently, Dr Edward Fujimoto, Wellness Program Manager at Castle Hospital, was on a TV program to explain this health hazard. He talked about dioxins and how bad they are for us. He said that we should not be heating our food in the microwave using plastic containers. This especially applies to foods that contain fat. He said that the combination of fat, high heat, and plastics releases dioxin into the food and ultimately into the cells of the body. Instead, he recommends using glass, such as Corning Ware, Pyrex or ceramic containers for heating food. You get the same results, only without the dioxin. So such things as TV dinners, instant ramen and soups, etc., should be removed from the container and heated in something else. Paper isn't bad but you don't know what is in the paper. It's just safer to use tempered glass, Corning Ware, etc. He reminded us that a while ago some of the fast food restaurants moved away from the foam containers to paper. The dioxin problem is one of the reasons.

Also, he pointed out that plastic wrap, such as Saran, is just as dangerous when placed over foods to be cooked in the microwave. As the food is nuked, the high heat causes poisonous toxins to actually melt out of the plastic wrap and drip into the food. Cover food with a paper towel instead.

Sunday, December 18, 2011

FY 2012 DOD Funding for Prostate Cancer

From: pcaroundtable-bounces@malecare.com [mailto:pcaroundtable-bounces@malecare.com] On Behalf Of Kevin Johnson
Sent: Friday, December 16, 2011 12:14 PM
To: PCa Roundtable
Subject: [Pcaroundtable] Approps - further analysis

Here is a little more information from an email I sent to my board this morning:
I just wanted to let you know that contained within the funding package that the House and Senate should pass tonight is $80 million for the Prostate Cancer Research Program at DOD. The PCRP was the only non-combat related stand alone program that maintained level funding from last year. The Medical Research Program which is a pot of money used to fund several smaller research programs was also level funded (at $50 million respectively).



Only 3 programs received increased funding over last year's funding level – Traumatic Brain Injury research, Orthopedic research and Gulf War Illness research.



All other programs were cut by 20% including Breast Cancer Research and Ovarian Cancer Research which are generally seen along with the PCRP as the main programs of the CDRMP because they've been around the longest.



Let me know if you have any questions.Kevin



Kevin S. Johnson

Sr. Vice President, Government Relations & Advocacy

ZERO – The Project to End Prostate Cancer

---------------------------------------------------------------------------

This

Wednesday, December 14, 2011

cardiovascular comorbidity is associated with treatment regret among men with recurrent prostate

The "New" Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services.
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
Copyright © 2008-11 Prostate Cancer International, Inc.Regret post-treatment in men with pre-existing cardiovascular disease
Posted on December 10, 2011 by Sitemaster
i 2 Votes

Another newly published paper, this time in the British Journal of Urology, addresses issues related to cardiovascular disease and the treatment of prostate cancer. However, in this case it is about the treatment of men who had an existing cardiovascular condition at the time of their initial treatment.

In this paper, Nguyen et al. sought to explore specifically whether cardiovascular comorbidity is associated with treatment regret among men with recurrent prostate cancer after first-line therapy. it has previously been demonstrated that treatment regret is associated with a lower level of educational attainment, non-White race, greater post-treatment declines in sexual function, and systemic symptoms.

Treatment regret can have an adverse impact on a patient’s overall outlook and has been associated with a poorer global quality of life. Understanding predictors of regret can help clinicians better counsel patients about their treatments so that later regret can be avoided. In previous studies, regret has been

The study was based on a retrospective analysis of data from 795 men enrolled in the Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma (COMPARE) registry. All patinets had a biochemical recurrence at an average (median) of 5.5 years after prostatectomy (n = 410), external beam radiation therapy (n = 237), brachytherapy (n = 124) or primary androgen deprivation therapy (n = 24).
The authors were able to show that:
14.8 percent of the patient cohort reported regret.
Patients with pre-existing cardiovascular comorbidity were more likely to experience post-therapy bowel toxicity (P = 0.022).
The factors significantly associated with increased treatment regret were
Cardiovascular comorbidity (adjusted odds ratio [AOR] = 1.52)
Younger age (AOR = 0.97 per year increase in age)
Bowel toxicity post-treatment (AOR = 1.58)
The authors conclude that the patients with pre-existing cardiovascular comorbidities were > 50 percent more likely to experience treatment regret than men without cardiovascular comorbidity, and that these data suggest that men with pre-existing cardiovascular comorbidities give additional consideration to active surveillance as a first-line form of management for newly diagnosed prostate cancer.
A further discussion of this paper on the Reuters web site provides supplementary information. In that discussion, Dr. Timothy Showalter, a radiation oncologist at Jefferson Medical College in Philadelphia who was not involved in the research is quoted as stating that “We’ve known for a while that men with other medical problems, like heart disease, may get a smaller benefit from radiation or surgery.” He want on to say that this study represents “another piece of evidence that supports closely monitoring men with prostate cancer” as opposed to implementing immediate treatment.
As noted by Reuters, “The study doesn’t show why patients with heart problems had more second thoughts about their treatment.” One possibility noted by the study’s lead author is that “men dealing with other diseases may not be able to cope with the extra distress from cancer treatment.”

It is important to note that this study only addresses regret in men who had a biochemical recurrence after first-line treatment and not all patients receiving first-line treatment for prostate cancer. As Dr. Nguyen is also quoted as saying, “This study tells men who have other diseases that maybe they should take a step back and not treat the cancer right away.”